Status:
COMPLETED
Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation
Lead Sponsor:
Timothy M. Bateman, MD
Conditions:
Myocardial Blood Flow Reserve
Eligibility:
All Genders
40-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the consistency of quantitative peak stress myocardial blood flow and myocardial blood flow reserve following a 10 second, 1 minute, 2 minute or 4 minute delay...
Eligibility Criteria
Inclusion
- Recent normal clinically-indicated exercise myocardial perfusion SPECT, treadmill maximal exercise test or exercise echocardiographic study
- No change in symptoms between the exercise study and PET study
- Capable of providing written informed consent
- BMI 25-32 kg/m2
Exclusion
- Diabetes mellitus
- Coronary Artery Calcium Score \>25
- Second and Third Degree Atrioventricular Node Block
- Sinus Node Dysfunction
- Recent Syncope of unknown etiology
- Left ventricular hypertrophy per ECG or echocardiography
- Slowed circulation times
- Active wheezing or with acute asthmatic or bronchospastic attacks requiring changes in therapy within the past 30 days.
- Patients that have experienced a previous hypersensitivity reaction thought to be related to Lexiscan
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01919450
Start Date
July 1 2013
End Date
April 1 2016
Last Update
August 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Luke's Hospital Imaging Center
Kansas City, Missouri, United States, 64111